Spiro<1,2,3,4-tetrahydronaphthalene-1,2'-oxirane> | 51605-29-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: Spiro<1,2,3,4-tetrahydronaphthalene-1,2'-oxirane>
• 英文别名: spiro-(1,2,3,4-tetrahydronaphthalen-1,2'-oxacyclopropane)；3,4-dihydro-2H-spiro[naphthalene-1,2’-oxirane]；3,4-dihydro-2H-spiro[naphthalene-1,2′-oxirane]；Spiro (1,2,3,4-tetrahydronaphthalene-1,2-oxiran)；Spiro(1,2,3,4-tetrahydronaphthalene-1,2'-oxirane)；3,4-dihydro-2H-spiro[naphthalene-1,2'-oxirane]；spiro[2,3-dihydro-1H-naphthalene-4,2'-oxirane]
• CAS: 51605-29-9
• 化学式: C₁₁H₁₂O
• 分子量: 160.216
• InChiKey: UYJPQDRVQBXHQR-UHFFFAOYSA-N

物化性质

• 沸点：
  85-90 °C(Press: 0.2 Torr)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  Spiro<1,2,3,4-tetrahydronaphthalene-1,2'-oxirane> 在 氯化亚砜 、 sodium azide 作用下， 以 吡啶 、 N,N-二甲基甲酰胺 、 均三甲苯 为溶剂， 生成 1,3,4,5-tetrahydrobenz[c,d]indole
  参考文献：
  名称：

  由1-四氢萘酮制备四氢苯并[ cd ]吲哚

  摘要：

  由易于获得的芳族酮（1）通过转化成环氧化物，用叠氮化物离子开环，脱水和热解所得的乙烯基叠氮化物来制备3，4-桥吲哚（5）。

  DOI：

  10.1016/s0040-4039(00)99311-0
• 作为产物：
  描述：

  3,4-二氢-1(2H)-萘酮 以65%的产率得到
  参考文献：
  名称：

  MOODY, CHRISTOPHER J.;BECK, ANTHONY L.;COATES, WILLIAM J., TETRAHEDRON LETT., 30,(1989) N0, C. 4017-418

  摘要：

  DOI：

文献信息

• Chemo-, regio-, and stereo-selective perfluoroalkylations by a Grignard complex with zirconocene
  作者：Motohiro Fujiu、Kazuyuki Negishi、Jie Guang、Paul G. Williard、Shigeki Kuroki、Koichi Mikami

  DOI：10.1039/c5dt03039k

  日期：——

  The synthesis of highly reactive perfluoroalkyl Grignard reagents with early transition metal zirconocene complexes and their new types of highly chemo-, regio-, and stereo-selective perfluoroalkylation reactions are reported with epoxides in particular. The zirconocene complex is advantageous in activating the perfluoroalkyl Grignard species. The zirconocene·Grignard complexes were clarified by DOSY

  据报道，具有早期过渡金属锆茂复合物的高反应性全氟烷基格氏试剂及其新型的高化学，区域和立体选择性全氟烷基化反应特别是与环氧化物一起使用。锆茂复合物在活化全氟烷基格氏试剂中是有利的。DOSY阐明了锆茂·格利雅（Grignard）配合物。两个1 H和19点˚FDOSY分析表明，MAO的添加和二恶烷，以R的混合物˚F的MgCl 1和Cp 2的ZrCl 2所连接的Cp 2 Zr的和R ˚F镁以生成所述锆茂/全氟烷基的格利雅/二恶烷复合物。
• Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
  申请人：Medivation Technologies, Inc.

  公开号：US09211287B2

  公开（公告）日：2015-12-15

  This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. The compounds may bind to and antagonize receptor α2B, α1B or α2A. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption, or to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. The compounds may also be used to treat diseases or conditions that are expected to be responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular, renal disorders or type 2 diabetes is particularly described.

  本公开涉及吡啶并[4,3-b]吲哚和吡啶并[3,4-b]吲哚衍生物。还提供了包含这些化合物的药物组合物，以及使用这些化合物在各种治疗应用中的方法，包括治疗认知障碍、精神障碍、神经递质介导的疾病和/或神经疾病。这些化合物可能结合并拮抗α2B、α1B或α2A受体。这些化合物可能在治疗中发挥作用，例如：（i）降低血压和/或（ii）促进肾脏血流和/或（iii）减少或抑制钠重吸收，或调节血糖水平，增加胰岛素分泌并治疗疾病或病况，对增加胰岛素产生有响应或预期有响应的疾病或病况。这些化合物还可用于治疗预期对降低血压有响应的疾病或病况。特别描述了使用这些化合物治疗心血管、肾脏疾病或2型糖尿病的方法。
• .beta.-Hydroxyarylethylimidazoles
  申请人：Rohm and Haas Company

  公开号：US04413003A1

  公开（公告）日：1983-11-01

  This invention relates to .beta.-hydroxyarylethylimidazoles, their enantiomorphs, acid addition salts and metal salt complexes. This invention also relates to the method of preparation and use of these compounds. These compounds and salts thereof are highly active broad-spectrum systemic fungicides effective in controlling phytopathgogenic fungi such as barley net blotch (Helminthosporium teres), grey mold (Botrytis cinerea), bean powdery mildew (Erysiphe polygoni), grape downy mildew (Plasmopora viticola), rice blast (Piricularia oryzae), tomato late blight (Phytophthora infestans), and wheat stem rust (Puccinia graminis f. sp. tritici race 15B-2).

  该发明涉及β-羟基芳基乙基咪唑，其对映体，酸盐和金属盐络合物。该发明还涉及这些化合物的制备方法和用途。这些化合物及其盐对诸如大麦网斑病（Helminthosporium teres）、灰霉病（Botrytis cinerea）、豆粉霉病（Erysiphe polygoni）、葡萄霜霉病（Plasmopora viticola）、稻瘟病（Piricularia oryzae）、番茄晚疫病（Phytophthora infestans）和小麦枝锈病（Puccinia graminis f. sp. tritici race 15B-2）等广谱系统性真菌具有高活性，有效控制作用。
• PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE
  申请人：Chakravarty Sarvajit

  公开号：US20140206711A1

  公开（公告）日：2014-07-24

  This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. The compounds may bind to and antagonize receptor α 2B , α 1B or α 2A . The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption, or to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. The compounds may also be used to treat diseases or conditions that are expected to be responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular, renal disorders or type 2 diabetes is particularly described.

  这份披露涉及吡啶并[4,3-b]吲哚和吡啶并[3,4-b]吲哚衍生物。提供了包括这些化合物的药物组合物，以及使用这些化合物进行各种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。这些化合物可以结合并拮抗受体α2B、α1B或α2A。这些化合物可以用于治疗，例如，（i）降低血压和/或（ii）促进肾血流和/或（iii）降低或抑制钠重吸收，或者调节血糖水平，增加胰岛素分泌，并治疗对增加胰岛素产生反应的疾病或状况。这些化合物还可以用于治疗预计会对降低血压产生反应的疾病或状况。特别描述了使用这些化合物治疗心血管、肾脏障碍或2型糖尿病的用途。
• PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]INDOLE DERIVATIVES AND METHODS OF USE
  申请人：Medivation Technologies, Inc.

  公开号：US20150258075A1

  公开（公告）日：2015-09-17

  This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. The compounds may bind to and antagonize receptor α2B, α1B or α2A. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption, or to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. The compounds may also be used to treat diseases or conditions that are expected to be responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular, renal disorders or type 2 diabetes is particularly described.

  本公开涉及吡啶并[4,3-b]吲哚和吡啶并[3,4-b]吲哚衍生物。所述化合物的制药组合物也提供，以及使用该化合物进行各种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。该化合物可能结合并拮抗α2B、α1B或α2A受体。该化合物可能用于治疗，例如：（i）降低血压和/或（ii）促进肾血流和/或（iii）减少或抑制钠重吸收，或调节血糖水平，增加胰岛素分泌并治疗预计对胰岛素产生增加反应的疾病或情况。该化合物还可用于治疗预计对血压降低有反应的疾病或情况。特别描述了使用该化合物治疗心血管、肾脏疾病或2型糖尿病的用途。